22.53 USD
+0.15 (+0.67%)
At close: Jan 30, 2026
22.53 USD
0 (0%)
After Hours: 1/30/2026, 4:30:02 PM
Overall ZYME gets a fundamental rating of 4 out of 10. We evaluated ZYME against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZYME as it has an excellent financial health rating, but there are worries on the profitability. ZYME is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- In the past year ZYME has reported negative net income.
- ZYME had a negative operating cash flow in the past year.
- ZYME had negative earnings in 4 of the past 5 years.
- In the past 5 years ZYME reported 4 times negative operating cash flow.
1.2 Ratios
- ZYME has a better Return On Assets (-15.97%) than 79.24% of its industry peers.
- ZYME has a better Return On Equity (-19.82%) than 83.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.97% | ||
| ROE | -19.82% | ||
| ROIC | N/A |
ROA(3y)-9.25%
ROA(5y)-23.15%
ROE(3y)-12.18%
ROE(5y)-33.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ZYME so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ZYME has less shares outstanding than it did 1 year ago.
- ZYME has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, ZYME has an improved debt to assets ratio.
2.2 Solvency
- ZYME has an Altman-Z score of 10.40. This indicates that ZYME is financially healthy and has little risk of bankruptcy at the moment.
- ZYME's Altman-Z score of 10.40 is amongst the best of the industry. ZYME outperforms 82.29% of its industry peers.
- There is no outstanding debt for ZYME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.4 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- ZYME has a Current Ratio of 6.94. This indicates that ZYME is financially healthy and has no problem in meeting its short term obligations.
- ZYME's Current ratio of 6.94 is fine compared to the rest of the industry. ZYME outperforms 70.10% of its industry peers.
- A Quick Ratio of 6.94 indicates that ZYME has no problem at all paying its short term obligations.
- ZYME has a better Quick ratio (6.94) than 70.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.94 | ||
| Quick Ratio | 6.94 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 34.37% over the past year.
- The Revenue has grown by 116.21% in the past year. This is a very strong growth!
- Measured over the past years, ZYME shows a very strong growth in Revenue. The Revenue has been growing by 20.93% on average per year.
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)116.21%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%72.59%
3.2 Future
- Based on estimates for the next years, ZYME will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.23% on average per year.
- Based on estimates for the next years, ZYME will show a very strong growth in Revenue. The Revenue will grow by 30.49% on average per year.
EPS Next Y27.6%
EPS Next 2Y30.03%
EPS Next 3Y17.44%
EPS Next 5Y18.23%
Revenue Next Year34.71%
Revenue Next 2Y61.35%
Revenue Next 3Y26.99%
Revenue Next 5Y30.49%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ZYME. In the last year negative earnings were reported.
- Also next year ZYME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ZYME's earnings are expected to grow with 17.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.03%
EPS Next 3Y17.44%
5. Dividend
5.1 Amount
- ZYME does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ZYMEWORKS INC / ZYME FAQ
What is the ChartMill fundamental rating of ZYMEWORKS INC (ZYME) stock?
ChartMill assigns a fundamental rating of 4 / 10 to ZYME.
What is the valuation status of ZYMEWORKS INC (ZYME) stock?
ChartMill assigns a valuation rating of 0 / 10 to ZYMEWORKS INC (ZYME). This can be considered as Overvalued.
Can you provide the profitability details for ZYMEWORKS INC?
ZYMEWORKS INC (ZYME) has a profitability rating of 1 / 10.
How financially healthy is ZYMEWORKS INC?
The financial health rating of ZYMEWORKS INC (ZYME) is 8 / 10.
Can you provide the expected EPS growth for ZYME stock?
The Earnings per Share (EPS) of ZYMEWORKS INC (ZYME) is expected to grow by 27.6% in the next year.